What are the immunohistochemical markers for osteoclastoma (giant‑cell tumor of bone)?

Immunohistochemical Markers for Osteoclastoma (Giant Cell Tumor of Bone)

The key diagnostic immunohistochemical marker for osteoclastoma is nuclear expression of H3.3 G34W mutant protein, which offers optimal diagnostic support and distinguishes GCTB from other giant cell-rich lesions, particularly osteosarcoma enriched in giant cells 1.

Primary Diagnostic Marker

H3.3 G34W (Histone H3F3A G34W mutant protein):

• Nuclear expression in mononuclear stromal cells (the neoplastic component)
• Sensitivity: 86.2-100% in various studies 2, 3
• This marker corresponds to the H3F3A gene mutation that characterizes both conventional and malignant GCTBs 1
• Remains positive even after denosumab treatment 2, 3
• Critical for differential diagnosis from giant cell-rich osteosarcoma 1

Cell Population-Specific Markers

The tumor comprises two distinct cell populations with different immunoprofiles:

Multinucleated Giant Cells (Osteoclast-like, Non-neoplastic):

• Iba1 (macrophage/osteoclast marker) - positive 4
• TRAP (tartrate-resistant acid phosphatase) - positive 4
• RANK (receptor activator of NFκB) - positive 4
• NFATc1 (mature osteoclast marker) - positive, but disappears after denosumab treatment 5, 3

Mononuclear Stromal Cells (Neoplastic component):

• SATB2 (osteoblast marker) - positive in 96.7-100% 2
• RUNX2 (osteoblast marker) - positive 4, 2, 3
• KPNA-2 (karyopherin α2) - positive 4
• p63 - positive in 100% of cases 2
• Osteocalcin - variable expression 4

Additional Markers

• FOS - progenitor osteoclast marker, expressed in ~11% of cells 5
• JDP2 - mature osteoclast marker 5
• Ki-67 - proliferation index assessment 4

Clinical Pearls and Pitfalls

Post-Denosumab Changes:

• After denosumab treatment, osteoclast-like giant cells disappear, but H3.3 G34W-positive neoplastic cells persist 2, 3
• The tumor undergoes dramatic morphologic changes with abundant bone formation and spindle cell proliferation 2, 3
• NFATc1 positivity decreases significantly (from 10% to 0.2%, P<0.001) after denosumab 5
• SATB2, RUNX2, and p63 remain positive in spindle cells and cells within the bone matrix 2

Diagnostic Algorithm:

1. First-line: H3.3 G34W immunohistochemistry for definitive diagnosis
2. If H3.3 G34W unavailable, use combination of SATB2 + RUNX2 + p63 in mononuclear cells
3. Confirm osteoclastic nature of giant cells with Iba1, TRAP, or RANK if needed
4. Always correlate with H3F3A mutation testing when available for confirmation 1

Critical Caveat: The osteoclast-like giant cells are not the neoplastic component but rather recruited non-neoplastic cells attracted by RANK-ligand overexpression from the neoplastic mononuclear stromal cells 1, 6. This is why denosumab (anti-RANK-ligand antibody) eliminates giant cells but leaves neoplastic cells intact, explaining the risk of recurrence after treatment cessation 1.